Table 2.

Clinical Characteristics of HEV-related patients and healthy control subjects.

Parameters Median (Range)	ALF-E(P) (N = 12)	AVH-E(P) (N = 44)	AVH-E(NP) (N = 10)	HC(P) (N = 20)	P Value
Median Age (years; range)	25	24	25	24	NS
	(21–31)	(18–31)	(20–36)	(19–30)
Median ALT (IU/L; range)	132	117	99	28*	P < 0.001
	(115–772)	(55–999)	(58–233)	(20–32)
Median AST (IU/L; range)	147	134	112	24.5*	P < 0.001
	(125–1583)	(60–2639)	(52–1538)	(20–28)
Median Bilirubin (mg/dl; range)	7.5	7	10	0.3*	P < 0.001
	(3.9–22)	(2–20)	(2–32)	(0.1–0.7)
Median INR (range)	3	1.2%	1.3%	1*	* and % P < 0.001
	(2.5–4)	(1.1–1.3)	(0.9–1.4)	(0.9–1.3)
Mortality	5/12	–	–	–	–
Median HEV RNA (Copies/mL)
High Viral Load = 2.64 x 105(2.33 x 105–1.6 x 106)	–	20%	16%	–	–
Low Viral Load = 3.2 x 103(3.25 x 103–2.65 x 104)	82%	80%	34%
Undetectable (less than 100 copies/ml)	18%		50%
Serum Albumin (g/dl)	3.05	–	–	–	–
	(2.8–3.35)
Arterial Ammonia (μgm/dl)	155	–	–	–	–
	(149–724)
Grade of Encephalopathy		–	–	–	–
I–II	7(60%)
III–IV	4(40%)
Hemoglobin (g/dl)	11	–	–	–	–
	(8.8–11.5)
Platelets (10 ∼ 9/l)	170	–	–	–	–
	(94–330)